KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives
International Journal of Molecular Sciences · 20.08.2024 · 25 (16) · 9023
DOI: 10.3390/ijms25169023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2024. Verfasst von Luca Guarnera und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44114, USA. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Gene Rearrangement, Leukemia. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AAMDSIF, Instituto of de Salud Carlos III.
Abstract (Originalsprache)
KMT2A (alias: mixed-lineage leukemia [MLL]) gene mapping on chromosome 11q23 encodes the lysine-specific histone N-methyltransferase 2A and promotes transcription by inducing an open chromatin conformation. Numerous genomic breakpoints within the KMT2A gene have been reported in young children and adults with hematologic disorders and are present in up to 10% of acute leukemias. These rearrangements describe distinct features and worse prognosis depending on the fusion partner, characterized by chemotherapy resistance and high rates of relapse, with a progression-free survival of 30–40% and overall survival below 25%. Less intensive regimens are used in pediatric patients, while new combination therapies and targeted immunotherapeutic agents are being explored in adults. Beneficial therapeutic effects, and even cure, can be reached with hematopoietic stem cell transplantation, mainly in young children with dismal molecular lesions; however, delayed related toxicities represent a concern. Herein, we summarize the translocation partner genes and partial tandem duplications of the KMT2A gene, their molecular impact, clinical aspects, and novel targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44114, USA.
- Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy.
- Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, CIBERER-Instituto de Salud Carlos III, University of Murcia, IMIB-Pascual Parrilla, 30005 Murcia, Spain.
ORCID-Profile: Luca Guarnera, Matteo D'Addona, Carlos Bravo-Perez, Valeria Visconte
Förderung
- AAMDSIF
- Instituto of de Salud Carlos III
Zitieren
APA
Guarnera, L., D'Addona, M., Bravo-Perez, C., & Visconte, V. (2024). KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. International Journal of Molecular Sciences, 25(16), 9023. https://doi.org/10.3390/ijms25169023
Vancouver
Guarnera L, D'Addona M, Bravo-Perez C, Visconte V. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. International Journal of Molecular Sciences. 2024;25(16):9023. doi:10.3390/ijms25169023
BibTeX
@article{Guarnera2024,
author = {Guarnera, Luca and D'Addona, Matteo and Bravo-Perez, Carlos and Visconte, Valeria},
title = {KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {16},
pages = {9023},
doi = {10.3390/ijms25169023}
}
EUVIMED